Digoxin FDA Link Generic

A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)

Also Known As:

Digitek; Lanoxicaps; Lanoxin; Digacin; Digoregen; Digoxina Boehringer; Digoxine Nativelle; Dilanacin; Hemigoxine Nativelle; Lanacordin; Lanicor; Lanoxin-PG; Lenoxin; Mapluxin; Boehringer, Digoxina; Lanoxin PG; Nativelle, Digoxine; Nativelle, Hemigoxine; Card-20(22)-enolide, 3- ((O- 2,6- dideoxy- beta- D- ribo- hexopyranosyl- (1- 4)- O- 2,6- dideoxy- beta- D- ribo- hexopyranosyl- (1- 4)- 2,6- dideoxy- beta- D- ribo- hexopyranosyl)oxy)- 12,14- dihydroxy- , (3beta,5beta,12beta)-

Pharmalogical Action Categories:

Anti-Arrhythmia Agents
Cardiotonic Agents
Enzyme Inhibitors

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Cardanolides
      - Cardiac Glycosides: 1002
        Cardenolides: 137
        Digoxin: 4157
        Digitalis Glycosides: 147
        Digoxin: 4157
Carbohydrates: 22023
- Glycosides: 2119
  - Cardiac Glycosides: 1002
    - Digitalis Glycosides: 147
      - Digoxin: 4157

Leonardo de Souza Teixeira Selected Research

Leonardo de Souza Teixeira Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure